Drug intelligence / Profile preview

MWTx 02

Development stage: Preclinical
Lead developer: Mabwell Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

MWTx 02 is a novel monoclonal antibody therapeutic developed by Mabwell Therapeutics for the treatment of autoimmune diseases and idiopathic thrombocytopenic purpura. It acts as an inhibitor of complement C1s, a serine protease that plays a key role in the activation of the classical complement pathway. By targeting and inhibiting C1s, MWTx 02 modulates the complement system, which is implicated in various immune-mediated and hematologic disorders. The drug is currently in preclinical development with parenteral administration being investigated[1][2][5].

Targets

C1S (Complement component 1s subcomponent serine protease)

Beyond the preview

Go deeper on MWTx 02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MWTx 02.

Explore the full profile